EMRA Rep to NIAID Advisory Board Application

Are you interested and have experience in COVID-19 care innovations and implementation in the ED?

EMRA is seeking an appointee to an Advisory Board for a 4 year grant awarded to ACEP by the NIH/NIAID which will be executed in partnership with RAND.  

We are looking for applicants who are familiar with:

  • Implementing new care and innovations in hospital Emergency Departments during the pandemic, and
  • The guidance and communications issued by professional societies such as EMRA and others that medical residents are likely to access for COVID-19 care in EDs. 

See more information about the study and Advisory Board below.

Deadline for applications is September 14.

The major goals of this study are to analyze the dissemination and implementation of care innovations for COVID-19 in hospital emergency departments (EDs) and to identify strategies to optimize diffusion of care innovations during pandemic and other rapidly evolving public health emergencies.  Specific aims include (1) analyzing the dissemination of care innovations for COVID-19 to ED clinicians through social media and other key communication channels, (2) examining the implementation and de-implementation of COVID-19 care innovations within hospital ED settings, and (3) identifying strategies for both disseminators and implementers to improve the diffusion of new practices during COVID-19 and similar public health emergencies.

The Advisory Board would meet approximately quarterly for the 4 years of the project, with an honorarium of $3000 per year as a gesture of appreciation. 

Other experts on the board include Emergency physician, nurse, NP, PA, respiratory therapy, and ID experts. Main roles include helping identify key COVID-related care innovations and communication channels for ED professionals, feedback on study design and interpretation of results, and later in the project, assisting with recommendations to improve the diffusion of care innovations and dissemination of findings. This is an important project to showcase emergency physicians rapid response to COVID-19.

Selection Timeline

EMRA Nominee Submission Deadline: September 14

Each submitted nomination must include:

  • CV
  • What relevant experience would you bring to this appointment? (<400 words)
  • How does this opportunity fit with your career interests and goals? (<300 words)
  • Attestation: If chosen to represent EMRA in this position, I commit to serving on this Advisory board for the next 4 years including quarterly meetings and associated preparation and quarterly updates to the EMRA Board of Directors. I understand that there is no additional funding for this position outside of the honorarium. 
  • Optional: Letter of recommendation

Attestation

If chosen to represent EMRA in this position, I commit to serving on this Advisory board for the next 4 years including quarterly meetings and associated preparation and quarterly updates to the EMRA Board of Directors. I understand that there is no additional funding for this position outside of the honorarium.

Submit

Related Content

Mar 23, 2025

Severe Finger Entrapment in Gas Filler Cap Valve of 2003 Ford Expedition

How do you manage a case of a patient's finger stuck so completely in a Ford Explorer gas valve that EMS arrives with part of the vehicle attached to your patient? Hint: Consider the use of a nasopharyngeal tube, an angle grinder, and DoorDash.

Nov 02, 2022

Critical Care Alert: A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest

Every minute counts for long-term outcomes in out-of-hospital cardiac arrest. Does the route of administration for lifesaving medications play a role? This EMRA Critical Care Alert dives into the PARAMEDIC-3 trial, comparing outcomes in OHCA patients who were treated with intraosseous access versus intravenous access.

Dec 09, 2025

Pseudo-Subarachnoid Hemorrhage Following Cervical Medial Branch Block Using Gadolinium-Based Contrast: A Case Report and Review of the Literature

This case report explores the evidence behind recognizing and treating conditions caused by gadolinium-based contrast agents — including pseudo-subarachnoid hemorrhage.